416 related articles for article (PubMed ID: 31068044)
1. Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
[TBL] [Abstract][Full Text] [Related]
2. Update on hairy cell leukemia.
Kreitman RJ; Arons E
Clin Adv Hematol Oncol; 2018 Mar; 16(3):205-215. PubMed ID: 29742076
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hairy cell leukemia.
Chihara D; Kreitman RJ
Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
5. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
6. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
7. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
8. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
9. Biology and Treatment of Hairy Cell Leukemia.
Paillassa J; Troussard X
Curr Treat Options Oncol; 2020 Apr; 21(6):44. PubMed ID: 32350628
[TBL] [Abstract][Full Text] [Related]
10. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic options for relapsed hairy cell leukemia.
Jain P; Polliack A; Ravandi F
Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
[TBL] [Abstract][Full Text] [Related]
12. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
[No Abstract] [Full Text] [Related]
13. How I manage patients with hairy cell leukaemia.
Thompson PA; Ravandi F
Br J Haematol; 2017 May; 177(4):543-556. PubMed ID: 28146266
[TBL] [Abstract][Full Text] [Related]
14. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
15. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
Falini B; Tiacci E
Hematol Oncol; 2019 Jun; 37 Suppl 1():30-37. PubMed ID: 31187521
[TBL] [Abstract][Full Text] [Related]
16. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
17. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
Robak T; Robak P
Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
[TBL] [Abstract][Full Text] [Related]
18. Hairy Cell Leukaemia.
Cross M; Dearden C
Curr Oncol Rep; 2020 Apr; 22(5):42. PubMed ID: 32297104
[TBL] [Abstract][Full Text] [Related]
19. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
20. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
